The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives
- PMID: 8751471
The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives
Abstract
The present study was aimed at analyzing the existence of an impaired complement system in CLL patients. For this purpose, the serum levels of the serum complement proteins C1q, C1r, C1s, C2, C3, C4, C5, C6, C7, C8, C9, Factor B and properdin were repeatedly evaluated by means of radial immunodiffusion assay in 26 CLL patients over a period of 2 years. At the time of diagnosis, 18 of the 26 CLL patients showed low serum levels in at least one of these complement proteins as compared to a group of sex- and age-matched healthy subjects (P < 0.0001). Complement defects affected either the classical and/or the alternative pathway components, and in some case low levels of late components (C5-C9) were also observed. A reduced level of properdin was the most frequent abnormality (11/18). The presence of such abnormalities were correlated with the stage of the disease, and they were found in 100% of the patients (11) in advanced stages (Rai II-IV), and in 40% of patients (15) in early stages (0-1) (P < 0.004). Severe infections occurred in five patients; four of them were in advanced stages of the disease and had decreased levels of at least one complement component, whereas the remaining patient was in an early stage and had normal levels of complement components. These data support the notion that an impaired complement system might be involved in the pathophysiology of CLL and its infectious complications. Although more work is needed to sustain this hypothesis, we discuss the possibility on the basis of data obtained in the first-degree relatives of CLL patients, that in some CLL patients the complement deficit might reflect a genetic predisposition.
Comment in
-
Complement values in B chronic lymphocytic leukemia: prognostic significance and correlation with cell maturation stage.Leukemia. 1998 Apr;12(4):635-6. doi: 10.1038/sj.leu.2400994. Leukemia. 1998. PMID: 9557626 No abstract available.
Similar articles
-
Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.Eur J Haematol. 2006 Jan;76(1):51-7. doi: 10.1111/j.1600-0609.2005.00553.x. Eur J Haematol. 2006. PMID: 16343271
-
Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression.Eur J Haematol. 2004 Jul;73(1):36-42. doi: 10.1111/j.1600-0609.2004.00269.x. Eur J Haematol. 2004. PMID: 15182336
-
Variable expression of CD49d antigen in B cell chronic lymphocytic leukemia is related to disease stages.Leukemia. 1996 Aug;10(8):1331-9. Leukemia. 1996. PMID: 8709639
-
[Hereditary complement deficiencies].Hautarzt. 1982 Feb;33(2):65-72. Hautarzt. 1982. PMID: 6281215 Review. German.
-
The properdin pathway: mechanisms of complement activation and analogies to the classical pathway.Rheumatology. 1975;6:2-16. Rheumatology. 1975. PMID: 1105744 Review. No abstract available.
Cited by
-
Second cancer incidence in CLL patients receiving BTK inhibitors.Leukemia. 2020 Dec;34(12):3197-3205. doi: 10.1038/s41375-020-0987-6. Epub 2020 Jul 23. Leukemia. 2020. PMID: 32704159 Free PMC article.
-
Genetic polymorphisms, chronic lymphocytic leukemia, and the future: are we there yet?Rev Bras Hematol Hemoter. 2014;36(1):5-6. doi: 10.5581/1516-8484.20140003. Rev Bras Hematol Hemoter. 2014. PMID: 24624026 Free PMC article. No abstract available.
-
CFP suppresses breast cancer cell growth by TES-mediated upregulation of the transcription factor DDIT3.Oncogene. 2019 Jun;38(23):4560-4573. doi: 10.1038/s41388-019-0739-0. Epub 2019 Feb 12. Oncogene. 2019. PMID: 30755730
-
Complement inhibition in cancer therapy.Semin Immunol. 2013 Feb;25(1):54-64. doi: 10.1016/j.smim.2013.04.001. Epub 2013 May 24. Semin Immunol. 2013. PMID: 23706991 Free PMC article. Review.
-
Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers.Int J Mol Sci. 2022 Sep 21;23(19):11113. doi: 10.3390/ijms231911113. Int J Mol Sci. 2022. PMID: 36232415 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous